CAMP4 Therapeutics (CAMP) Earnings Analysis
CAMP4 Therapeutics (CAMP) next reports earnings on 2026-08-13, consensus EPS -0.24 USD. Last quarter (2026-05-07) it missed with EPS -0.32 USD vs -0.21 USD est (-52.4%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -1.37.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CAMP next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.24 USD |
| Revenue estimate | 0.00B |
CAMP earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.32 USD | -0.21 USD | -52.4% | Miss |
| 2026-03-05 | -0.87 USD | -0.31 USD | -180.6% | Miss |
| 2025-11-06 | -0.55 USD | -0.47 USD | -17% | Miss |
| 2025-08-14 | -0.62 USD | -0.67 USD | +7.5% | Beat |
| 2024-11-21 | -24.19 USD | -1.07337 USD | -2153.6% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
CAMP valuation and analyst view
| Trailing P/E | -1.37 |
|---|---|
| Trailing EPS | -1.48991 USD |
| Price / book | 5.83 |
| Dividend yield | 0.00% |
| Market cap | 0.07B |
| Analyst consensus | Buy (17 buy / 6 hold / 1 sell) |
| Avg price target | 6.5 USD |
Related research pages
Frequently asked questions
When is CAMP4 Therapeutics (CAMP)'s next earnings date?
CAMP4 Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.24 USD and revenue estimate of 0.00B.
Did CAMP beat earnings last quarter?
In its 2026-05-07 report, CAMP posted EPS of -0.32 USD versus a -0.21 USD estimate — a miss of 52.4%.
What is CAMP's earnings track record?
Over the last 5 reported quarters with consensus data, CAMP beat estimates 1 times (20%).
What is CAMP's current P/E ratio and EPS?
CAMP trades at a trailing P/E of -1.37 on trailing EPS of -1.4899089446570672 USD.
What do analysts rate CAMP?
Analyst consensus is "Buy" across 24 ratings (0 strong buy, 17 buy, 6 hold, 1 sell, 0 strong sell). Average 12-month price target: 6.5 USD.